Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics Inc (TNYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,212
  • Shares Outstanding, K 87,583
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,080 K
  • EBIT $ -123 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.57
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings $-0.28 on 03/10/25
  • Next Earnings Date 03/17/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 344.26% ( +76.95%)
  • Historical Volatility 243.99%
  • IV Percentile 94%
  • IV Rank 53.92%
  • IV High 626.84% on 02/28/25
  • IV Low 13.65% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 270
  • Volume Avg (30-Day) 439
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 12,601
  • Open Int (30-Day) 11,662

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.31
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +52.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3941 +77.34%
on 03/04/25
1.2400 -43.64%
on 02/18/25
-0.5011 (-41.76%)
since 02/14/25
3-Month
0.3941 +77.34%
on 03/04/25
2.9200 -76.07%
on 12/16/24
-2.0511 (-74.59%)
since 12/13/24
52-Week
0.3941 +77.34%
on 03/04/25
5.3900 -87.03%
on 03/18/24
-4.0711 (-85.35%)
since 03/14/24

Most Recent Stories

More News
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Announces Pricing of Public Offering

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Announces Proposed Public Offering

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 Gene Therapy on December 17

Tenaya Therapeutics will announce Phase 1b/2 trial data for TN-201 gene therapy on December 17, 2024.Quiver AI SummaryTenaya Therapeutics, Inc., a biotechnology company focused on developing therapies...

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

TNYA : 0.6989 (+4.28%)
Tenaya Therapeutics Doses First Patient in RIDGE-1 Clinical Trial of TN-401 Gene Therapy for PKP2-associated ARVC

Tenaya Therapeutics initiates RIDGE-1 trial for TN-401 gene therapy targeting PKP2 mutations in ARVC patients. Initial data expected in 2025.Quiver AI SummaryTenaya Therapeutics announced the first patient...

TNYA : 0.6989 (+4.28%)

Business Summary

Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH...

See More

Key Turning Points

3rd Resistance Point 0.8236
2nd Resistance Point 0.7812
1st Resistance Point 0.7401
Last Price 0.6989
1st Support Level 0.6566
2nd Support Level 0.6142
3rd Support Level 0.5731

See More

52-Week High 5.3900
Fibonacci 61.8% 3.4816
Fibonacci 50% 2.8921
Fibonacci 38.2% 2.3025
Last Price 0.6989
52-Week Low 0.3941

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar